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M1a esophagus cancer have a poorer
prognosis than patients with M0 disease.
We would like to thank Drs. Scho-
mas, Miller, and Quevedo for the oppor-
tunity to discuss and further clarify our
data. Their letter specifically requests
for additional data and comment on the
nonoperative patients treated with che-
moradiation. Our 2-year overall and dis-
ease-specific survival rates for patients
with M1a disease were 13% and 11%,
respectively, for this group.
To answer the question about a
comparison of patients staged as M1a
versus N1, we have included Figure 1
with this response letter. When staging
M1a versus M1b disease, we followed
the guidelines of the American Joint
Committee on Cancer staging system.
We did not attempt to differentiate sta-
tions 17 (left gastric), 18 (common he-
patic), and 20 (celiac) from each other.
These stations were collectively consid-
ered M1a disease for patients with lower
esophagus and gastroesophageal can-
cers. Surgical staging can clearly distin-
guish these separate nodal stations.
However, nodes in these stations appear
similar on computed tomography imag-
ing. Radiology reports do not and cannot
clearly distinguish this difference.
The main point of this query is
that patients with locally advanced
esophagus cancer, even stage M1a, de-
serve the opportunity to receive defini-
tive therapy because a few of them can
be cured by this approach, especially if
they fit within the highly selective cate-
gory of operative patients. First, we only
had 10 patients with M1a disease who
underwent esophagectomy. These
tended to be younger patients without
medical comorbidities who were fit
enough to receive trimodality therapy.
Most received chemoradiation alone.
We certainly agree that chemoradiation
can cure a few patients with locally
advanced esophageal cancer. However,
our survival outcomes with nonopera-
tive therapy for patients with M1a disease
clearly fall into the “dismal” category.
Although 13% of our patients survived 2
years, almost all the remaining patients
died of their esophagus cancer. For them,
the treatment was largely palliative.
Clearly, newer innovative therapy is
needed for this dreaded disease.
The treatment options for patients
with locally advanced esophagus cancer
have not changed since the 1980s. Ra-
diation Therapy Oncology Group 8501,
initiated in 1986, used cisplatin, 5-FU,
and 50 Gy in the chemoradiation arm of
this trial for inoperable patients.2 For
operable patients, a randomized trial
published by Walsh et al.3 used cispla-
tin, 5-FU, and 40 Gy preoperatively.
With the exception of some minor vari-
ations in radiation technique, both these
trials continue to drive therapy today.
Newer therapies are needed if we are to
improve outcome for these patients.
With respect to radiation therapy, trials
applying newer techniques to deliver in-
creased doses are warranted, such as
intensity modulation, image guidance,
and even proton therapy. Likewise, the
era of individualized therapy should ap-
ply to trials for patients with esophagus
cancer, mirroring distinctions being
made in therapies for lung and other
aerodigestive cancers.
Jeffrey Bradley, MD
Issam El Naqa, PhD
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Staging in Lung Cancer
To the Editor:
The answer to the last frequently
asked question included in the Inter-
national Association for the Study of
Lung Cancer Staging Manual in Tho-
racic Oncology (Table 1)1 has been
met with concern by the members of
the Bronchogenic Carcinoma Cooper-
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FIGURE 1. Disease-specific survival comparison for N1 versus M1a status in pa-
tients with locally advanced carcinoma of the esophagus.
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ative Group of the Spanish Society of
Pneumology and Thoracic Surgery.
To classify as pathologic (p) N2 a
tumor that has not been resected, even if
there is pathologic confirmation of the
metastatic nature of the lymph nodes by
means of any preoperative endoscopy
(transbronchial needle aspiration, ultra-
sonography-assisted bronchoscopy, or
oesophagoscopy with fine needle aspira-
tion), percutaneous needle aspiration, or
surgical exploration (mediastinoscopy,
mediastinotomy, extended cervical me-
diastinoscopy, or thoracoscopy) goes
against general rule 2 of the tumor (T),
node (N), metastasis (M) classification
of malignant tumors, which says “Clin-
ical classification (. . .) is based on evi-
dence acquired before treatment. Such
evidence arises from physical examina-
tion, imaging, endoscopy, biopsy, surgi-
cal exploration, and other relevant ex-
aminations.”2 “Pathologic classification
(. . .) is based on the evidence acquired
before treatment, supplemented or mod-
ified by the additional evidence acquired
from surgery and from pathologic exam-
ination (. . .)” and “entails a resection of
the primary tumor or biopsy adequate to
evaluate the highest pT category (. . .)”
and “the removal of nodes (. . .).” “An
excisional biopsy alone of a lymph node
without pathologic assessment of the
primary is insufficient to fully evaluate
the pN category and is a clinical classi-
fication (. . .).”2
Back, at least, to the early 1990s,
some chest physicians and oncologists,
mainly in North America, started to
think that pathologic confirmation of tu-
mor extent in the pretreatment assess-
ment of lung cancer entitled them to
assign a pathologic classification to
these tumors. This is an evident misin-
terpretation of the word “pathologic” in
the context of the TNM classification
and a violation of the general rule 2.
This misinterpretation eventually found
its way into medical writing, as we
pointed out in 2004.3 Now, 5 years later,
this schismatic use of the “p” prefix
seems to be explicitly sanctioned by the
International Association for the Study
of Lung Cancer.
There are important implications
associated with this misunderstanding
that go beyond mere taxonomy. Accord-
ing to the general rules, even if a cyto-
histologically diagnosed tumor has
pathologic evidence of nodal disease, its
classification will still be clinical by def-
inition, because the tumor has not been
resected. If we assign “p” status to tu-
mors that have not been resected, we
will be mixing tumors with very differ-
ent prognosis, i.e., tumors with patho-
logic confirmation of their anatomic ex-
tent but that do not undergo resection
and tumors that have been resected and
have a proper pathologic classification.
The Certainty Factor4 offers the possi-
bility to code in a different way those
nodes considered involved by imaging
methods and by pathologic confirmation
in the clinical phase of the tumor clas-
sification without relying to the “p” pre-
fix, which should be reserved for patho-
logic classification, only.
In conclusion, assigning “p” status
to unresected tumors that have pathologic
confirmation of their nodal extent goes
against general rule 2 of the TNM classi-
fication; it produces a mixture of cases of
different prognosis that undermines the
prognostic capacity of the TNM classifi-
cation for lung cancer gained by the revi-
sions that lead to its 7th edition, and there-
fore, it should be avoided.
A´ngel Lo´pez-Encuentra, MD
Pulmonology Service
Hospital Universitario 12 de Octubre
Madrid, Spain
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In Response:
We are grateful to the editor for
an opportunity to respond to this ques-
tion, which it is proposed to publish in
the Journal of Thoracic Oncology. We
should emphasize that the chapters in
the IASLC Manual on Thoracic Stag-
ing1 to which the comments are ad-
dressed, and many other chapters in
this book, and the companion IASLC
Handbook of Staging in Thoracic On-
cology,2 were reproduced with the per-
mission of the International Union
Against Cancer from publications to
be published later this year: the TNM
Classification of Malignant Tumors
7th edition and the TNM Supplement:
A Commentary on Uniform Use 4th
edition. Fuller explanatory notes will
be available in these publications.
The International Association for
the Study of Lung Cancer was accorded
the privilege of publishing these chap-
ters ahead of the source material because
of its central role in formulating the
proposals for the 7th edition and delays
in the publishing schedules of the Inter-
national Union Against Cancer and the
American Joint Committee on Cancer,
the two bodies that administer the tu-
mor, node, metastasis (TNM) classifica-
tion worldwide. In no sense was it the
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TABLE 1. Frequently Asked Question and Answer1
Question Clinical classification suggested that our patient had a T2 N2 M0 NSCLC. Preoperative
biopsy of ipsilateral mediastinal nodes confirmed N2 disease, and a thoracotomy was
not undertaken. Should this case be classified as cN2 or pN2? Should this case now
be assigned a pathologic stage?
Answer Microscopic confirmation of the nodal disease would allow this to be classified as pN2.
However, to be designated a pathologic stage, the primary tumor must also have
been confirmed on biopsy to establish the pT category.
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